Raptiva News and Research

RSS
Raptiva (efalizumab) is a recombinant humanized monoclonal antibody that binds to human CD11a, the alpha-subunit of Leukocyte Function Antigen-1 (LFA-1) and inhibits the LFA-1/ICAM-1 interaction. Raptiva is an FDA-approved medication for treatment of mild-to-moderate psoriasis.
Leukothera effectively treats psoriasis in humanized mouse xenograft transplantation model

Leukothera effectively treats psoriasis in humanized mouse xenograft transplantation model

BioTrends' Stelara second wave report finds increase in prescribing among dermatologists

BioTrends' Stelara second wave report finds increase in prescribing among dermatologists

Dermatologists express strong interest in Stelara, despite concerns

Dermatologists express strong interest in Stelara, despite concerns

Rituximab linked to viral brain infection

Rituximab linked to viral brain infection

Withdrawal of Raptiva from U.S. market

Withdrawal of Raptiva from U.S. market

CytoDyn responds to FDA as high court rules agency cannot guarantee drug safety

CytoDyn responds to FDA as high court rules agency cannot guarantee drug safety

FDA issues warning on psoriasis drug Raptiva (efalizumab)

FDA issues warning on psoriasis drug Raptiva (efalizumab)

FDA approves new labeling for psoriasis drug Raptiva

FDA approves new labeling for psoriasis drug Raptiva

Efalizumab effective in treatment of heavy psoriasis

Efalizumab effective in treatment of heavy psoriasis

NICE backs use of Enbrel and Raptiva to treat severe psoriasis

NICE backs use of Enbrel and Raptiva to treat severe psoriasis

Clinical benefit for moderate-to-severe plaque psoriasis patients treated with Raptiva for 30 months

Clinical benefit for moderate-to-severe plaque psoriasis patients treated with Raptiva for 30 months

FDA approves new drug Enbrel for psoriasis

FDA approves new drug Enbrel for psoriasis

Raptiva, 20 percent improvement in an individual's signs and symptoms of arthritis.

Raptiva, 20 percent improvement in an individual's signs and symptoms of arthritis.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.